Published on
November 30, 2017
- 23:51 GMT
FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder
The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal ( …
Distribution channels:
Healthcare & Pharmaceuticals Industry
